CONSIDER USING CBD WHEN TAKING NEUROTOXIC CHEMOTHERAPY OR OTHER DRUGS

If you have any doubts with regard to the efficacy of CBD for treatment of neuropathic pain, please enjoy the references, a lot of references, at the bottom of this blog. I mostly chose references where whole plant CBD rich extracts were being used, as this is what we have in our medical cannabis medicine cabinet.

So, if we agree that CBD is a safe way to often ameliorate the pain of drug induced, and other neuropathic pain, AND we note that CBD is clearly neuro-protective, why not give it in low dose to patients who are taking any potential neurotoxic medication. It clearly cannot hurt and doing this in a study form would/could/should be pretty easy.

There are millions of patients in the US taking drugs with potential neuro-toxicity. The cost in pain and dollars is immense. I often see cancer patients in remission from their cancer for years, but are nearly fully debilitated from neuropathic pain. They often can’t feel the bottom of their feet, so they can’t drive and have difficulty with walking. The pain itself, can be “suicidal level” pain.

Anyone interested in starting an informal study for a few years and see what happens?

 

ARTICLES FROM GW PHARMA:(They use “Sativex” which is a whole plant 1:1 CBD:THC extract

 

GWPharma – New Published Study Shows Sativex® Successfully Treats Neuropathic PainRelevance: 904

 

New Published Study Shows Sativex® Successfully Treats Neuropathic Pain New Published Study Shows Sativex® Successfully Treats Neuropathic Pain New Published Study Shows Sativex® Successfully Treats Neuropathic Pain 12 November 2007 GW Pharmaceuticals plc (AIM: GWP) today announces that The I…
GWPharma – Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant PatientsRelevance: 902

 

Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients Results of Sativex® Phase III Neuropathic Pain Trials Demonst…
GWPharma – Neuropathic PainRelevance: 902

 

Cancer Pain Neuropathic Pain Other Mechanism of Action Home Sativex Sativex R Therapeutic Uses NeuropathicPainNeuropathic Pain Neuropathic pain is a chronic, debilitating and widespread condition with an estimated prevalence of one per cent of the general population. Neuropathic pain ar…
GWPharma – Start of Second Phase III Trial in MS Neuropathic PainRelevance: 887

 

Start of Second Phase III Trial in MS Neuropathic Pain Start of Second Phase III Trial in MS Neuropathic Pain Start of Second Phase III Trial in MS Neuropathic Pain 9 August 2006 Porton Down, UK, 9 August 2006 – GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase I…
GWPharma – GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic PainTrialRelevance: 876

 

GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic Pain Trial GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic Pain Trial GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuro…
GWPharma – Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient RecruitmentRelevance: 867

 

Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment Sativex® Phase III Trial in MS Neuropathic PainCompletes Patient Recruitment Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment 30 August 2007 GW Pharmaceuticals plc (AIM: GWP) announces …
GWPharma – New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS NeuropathicPainRelevance: 859

 

New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain 17 O…
GWPharma – Preliminary Results from Sativex® Phase III Multiple Sclerosis spasticity studyRelevance: 839

 

…e GW with a regulatory route in Europe for the spasticity indication, the bulk of our positive clinical data relates to neuropathic pain. We have two further Phase III neuropathic pain studies due to report later this year and we need to consider with our marketing partners the relative benefits of …
GWPharma – Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple SclerosisRelevance: 831

 

Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis Sativex®, a Cannabis-Based Medicine, Significantly Reduces Ce…
GWPharma – GW Announces Regulatory Approval of Sativex® in CanadaRelevance: 828

 

GW announces that Sativex® has been granted regulatory approval in Canada for the symptomatic relief of neuropathicpain in multiple sclerosis. GW announces that Sativex® has been granted regulatory approval in Canada for the symptomatic relief ofneuropathic pain in multiple sclerosis. Dr Geoffr…
GWPharma – GW Announces Positive Results From Each of Four Phase Three Clinical TrialsRelevance: 820

 

…le-blind, placebo-controlled Phase III trials included approximately 350 patients suffering from Multiple Sclerosis and neuropathicpain Each of the four trials reported positive data, including statistically significant reductions in neuropathic pain, spasticity and sleep disturbance As a result …
GWPharma – Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic PainRelevance: 801

 

Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic Pain Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic Pain Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic Pain 22 October 2007 GW Pharmaceuticals plc (GWP:AIM) announces positive …
GWPharma – Clarification Re: Press CommentRelevance: 755

 

…arch proposition – that there is scientific evidence to suggest that cannabis based medicines are effective in treating neuropathicpain and spasticity, two of the principal symptoms of multiple sclerosis. In clinical trials carried out by GW to date on patients suffering from multiple sclerosis and…
GWPharma – Clinical TrialsRelevance: 751

 

Sativex Cancer Pain Trials In August 2007 GW announced the approval (NOC/c) in Canada of Sativex® as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pai…
GWPharma – OtherRelevance: 714

 

Cancer Pain Neuropathic Pain Other Mechanism of Action Home Sativex Sativex R Therapeutic Uses Other Other Rheumatoid arthritis Sativex showed positive results in Phase II placebo-controlled trial in treating pain due to rheumatoid arthritis (RA). RA is the commonest form of inflammatory…
GWPharma – Phase III MS Neuropathic Pain Trial Preliminary ResultsRelevance: 714

 

Phase III MS Neuropathic Pain Trial Preliminary Results Phase III MS Neuropathic Pain Trial Preliminary Results Phase III MSNeuropathic Pain Trial Preliminary Results 8 April 2008 GW Pharmaceuticals plc (AIM: GWP) announces preliminary results of a Phase III double-blind randomised placebo-c…
GWPharma – GW Commences Sativex® Phase III Clinical Trial in MS SpasticityRelevance: 694

 

… two potential short term opportunities to re-submit Sativex for regulatory approval in Europe. In the indication of MS NeuropathicPain, a second pivotal Phase III trial has already completed patient recruitment and is due to report headline results in the first quarter of 2008. This could lead to …
GWPharma – GW and Almirall Announce European Development and Marketing Agreement for Sativex®Relevance: 676

 

Sativex is in Phase III trials for the treatment of Multiple Sclerosis symptoms (neuropathic pain and spasticity), neuropathic pain(peripheral and general) and cancer pain. Under the agreement GW is responsible for completing the development of Sativex for these three indications. In addition to …
GWPharma – Sativex® Launched in Canadian Market by Bayer HealthCareRelevance: 664

 

…tivex is now available by prescription through Canadian pharmacies as an adjunctive treatment for symptomatic relief of neuropathicpain in adults with multiple sclerosis (MS). GW is pleased to announce that, following the receipt of regulatory approval from Health Canada, Sativex is now available …
GWPharma – GW Files Sativex® for Approval in Selected European Countries for MS SpasticityRelevance: 659

 

…d. In addition to MS spasticity, Sativex is also in Phase III trials for three further separate indications: peripheral neuropathic pain, MS neuropathic pain and cancer pain. It is intended that, in accordance with conventional regulatory requirements, each regulatory submission for each target indi…
GWPharma – Multiple SclerosisRelevance: 657

 

Cancer Pain Neuropathic Pain Other Mechanism of Action Home Sativex Sativex R Therapeutic Uses Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis (MS) is the most common disabling neurological condition affecting young adults. According to the World Health Organization, MS affects m…
GWPharma – Positive Results in Randomized Withdrawal Sativex® Study Confirm Long Term Efficacy in MS SpasticityRelevance: 654

 

…er 2008, GW reported positive results from a placebo-controlled randomized withdrawal study of Sativex in patients with neuropathicpain due to MS. The results reported today are from a study with a similar design but in patients with a different MS symptom. Taken together, these studies show that t…
GWPharma – Sativex® receives Qualifying Notice for approval in Canada for the relief of Cancer PainRelevance: 653

 

Sativex® receives Qualifying Notice for approval in Canada for the relief of Cancer Pain Sativex® receives Qualifying Notice for approval in Canada for the relief of Cancer Pain Sativex® receives Qualifying Notice for approval in Canada for the relief of CancerPain 22 October 2007 GW Pharmac…
GWPharma – Press ReleasesRelevance: 648

 

Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain 26 November 2007 GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announced that the first US Phase II/III dose-ranging trial has been initiated to evaluate the efficacy and safety of Sative… more New …
GWPharma – GW and Bayer Extend Marketing Agreement For Sativex to Canadian MarketRelevance: 641

 

…eptable cannabis-derived product for the treatment of the debilitating symptoms of Multiple Sclerosis (“MS”) and severe neuropathicpain. The product is a whole plant medicinal cannabis extract containing TetranabinexTM (tetrahydrocannabinol (“THC”)) and NabidiolexTM (cannabidiol (“CBD”)) as its pri…
GWPharma – Catalan Government Reports Positive Outcome of Sativex Access ProgrammeRelevance: 629

 

…istered as an oro-mucosal spray authorized in Canada under the brand name Sativex® as a co-adjuvant in the treatment ofneuropathic pain in people with multiple sclerosis (MS). This project, promoted by the Catalan Health Department, has involved the participation of over 40 doctors in 6 hospitals …
GWPharma – UK Regulatory Update Medicines Commission Confirms Further Clinical Efficacy Data RequiredRelevance: 625

 

Meanwhile, Sativex has received regulatory approval in Canada in the treatment of Neuropathic Pain in MS. The product is due for Canadian launch imminently. Professor Mike Barnes, President of the World Federation of Neuro-rehabilitation, Chairman of the Royal College of Physicians Rehabilitation …
GWPharma – GW receives Qualifying Notice for approval in Canada for Sativex®Relevance: 625

 

Sativex will initially be indicated in Canada for the relief of neuropathic pain in Multiple Sclerosis (“MS”). GW filed its Sativex application with Health Canada under the Notice of Compliance with conditions (NOC/c) policy. The Qualifying Notice confirms that Sativex qualifies to be considered f…
GWPharma – Health Canada Approves Sativex® For Cancer PainRelevance: 616

 

Health Canada Approves Sativex® For Cancer Pain Health Canada Approves Sativex® For Cancer Pain Health Canada Approves Sativex® For Cancer Pain 7 August 2007 GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announce that Health Canada has approved Sativex®, a …
GWPharma – Prescriber InformationRelevance: 610

 

…proval for MS spasticity in New Zealand and achieved approval in Israel for the two indications of MS Spasticity and MS neuropathicpain. In Canada, as well as being approved for the treatment of spasticity due to multiple sclerosis, Sativex is also approved under the Notice of Compliance with Condi…
 
NON GW ARTICLES 

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

Jensen B, Chen J, Furnish T, Wallace M.

Curr Pain Headache Rep. 2015 Oct;19(10):524. doi: 10.1007/s11916-015-0524-x.

PMID:
26325482
2.

[Clinical pharmacology of medical cannabinoids in chronic pain].

Ing Lorenzini K, Broers B, Lalive PH, Dayer P, Desmeules J, Piguet V.

Rev Med Suisse. 2015 Jun 24;11(480):1390, 1392-4. Review. French.

PMID:
26267945
3.

[Cannabinoids in neurology–Brazilian Academy of Neurology].

Brucki SM, Frota NA, Schestatsky P, Souza AH, Carvalho VN, Manreza ML, Mendes MF, Comini-Frota E, Vasconcelos C, Tumas V, Ferraz HB, Barbosa E, Jurno ME.

Arq Neuropsiquiatr. 2015 Apr;73(4):371-4. doi: 10.1590/0004-282X20150041. Epub 2015 Apr 1. Portuguese.

4.

The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.

Boychuk DG, Goddard G, Mauro G, Orellana MF.

J Oral Facial Pain Headache. 2015 Winter;29(1):7-14. doi: 10.11607/ofph.1274. Review.

PMID:
25635955
5.

Cannabidiol: promise and pitfalls.

Welty TE, Luebke A, Gidal BE.

Epilepsy Curr. 2014 Sep;14(5):250-2. doi: 10.5698/1535-7597-14.5.250.

6.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

Moreno Torres I, Sanchez AJ, Garcia-Merino A.

Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.

PMID:
25331416
7.

A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.

Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, Taylor L, Lauder H, Serpell M.

J Neurol. 2015 Jan;262(1):27-40. doi: 10.1007/s00415-014-7502-9. Epub 2014 Sep 30.

PMID:
25270679
8.

Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation.

Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O’Sullivan SE.

J Pharmacol Exp Ther. 2014 Nov;351(2):457-66. doi: 10.1124/jpet.114.217125. Epub 2014 Sep 11.

PMID:
25212218
9.

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic paintreatment.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E.

Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13.

PMID:
24420962
10.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
11.

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.

Br J Pharmacol. 2014 Feb;171(3):636-45. doi: 10.1111/bph.12439.

12.

Therapeutic potential of cannabinoid medicines.

Robson PJ.

Drug Test Anal. 2014 Jan-Feb;6(1-2):24-30. doi: 10.1002/dta.1529. Epub 2013 Sep 4. Review.

PMID:
24006213
13.

Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.

Tanasescu R, Constantinescu CS.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28. doi: 10.1517/17425255.2013.795542. Epub 2013 Apr 27. Review.

PMID:
23621668
14.

[Marihuana and cannobinoids as medicaments].

Tkaczyk M, Florek E, Piekoszewski W.

Przegl Lek. 2012;69(10):1095-7. Review. Polish.

PMID:
23421098
15.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.

J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.

PMID:
23180178
16.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

17.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
18.

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.

Notcutt WG.

Prim Health Care Res Dev. 2013 Apr;14(2):192-9. doi: 10.1017/S1463423612000333. Epub 2012 Jul 12.

PMID:
22784399
19.

Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L.

J Exp Med. 2012 Jun 4;209(6):1121-34. doi: 10.1084/jem.20120242. Epub 2012 May 14.

20.

New pain drugs in pipeline, but challenges to usage remain.

Brower V.

J Natl Cancer Inst. 2012 Apr 4;104(7):503-5. doi: 10.1093/jnci/djs199. Epub 2012 Mar 22. No abstract available.

Author
Allan Frankel, MD

You Might Also Enjoy...

CANNABIS AND CANCER

This article covers the various aspects of cancer care involving the use of Medical Cannabis